Indication¹

Opdivo in combination with YERVOY or chemotherapy is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell PD-L1 expression ≥ 1 %.

CheckMate 648²

CheckMate 648 is a randomized, open-label, phase 3 trial comparing OPDIVO + YERVOY or OPDIVO + chemotherapy with chemotherapy in patients with previously untreated, unresectable advanced, recurrent, or metastatic esophageal squamous-cell carcinoma.

The trial was not designed to compare OPDIVO + chemotherapy with OPDIVO + YERVOY.

A 29-month follow-up on efficacy and safety was published in Cancer Med. May 2024.

References: 

1. OPDIVO SmPC.
2. Kato K, Doki Y, Chau I, et al. Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29-month follow-up from a randomized, open-label, phase III trial. Cancer Med. 2024;13:e7235. doi:10.1002/cam4.7235